Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers. Keller PJ, Adams EJ, Wu R, Cote A, et al. Cancer Res 2024;84:2501-2517.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Keller PJ, Adams EJ, Wu R, Cote A, et al. Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers. Cancer Res 2024;84:2501-2517.
PMID: 38833522